Trials / Completed
CompletedNCT00920218
Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 121 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this observer-blind study is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' investigational Herpes Zoster vaccine GSK1437173A when administered as 2 doses or 3 doses to hematopoietic stem cell transplant (HCT) recipients.
Detailed description
The Protocol Posting has been updated following Protocol amendment 2, Sep 2009. The sections impacted are: eligibility criteria.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Herpes Zoster Vaccine 1437173A | Different formulations of investigational vaccine (GSK 1437173A) administered in 2 or 3 doses intramuscularly. |
| BIOLOGICAL | Placebo vaccine (saline) | 1 or 3 doses of Placebo (saline) injected intramuscularly. |
Timeline
- Start date
- 2009-07-14
- Primary completion
- 2011-04-26
- Completion
- 2012-03-21
- First posted
- 2009-06-15
- Last updated
- 2017-12-12
- Results posted
- 2017-12-12
Locations
11 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00920218. Inclusion in this directory is not an endorsement.